metoject pen 17,5 mg
medac gesellscaft fur klinische spezialprÄparate - germania - methotrexatum - sol. inj. in stilou injector (pen) preumplut - 17,5mg - imunosupresoare alte imunosupresoare
metoject pen 20 mg
medac gesellscaft fur klinische spezialprÄparate - germania - methotrexatum - sol. inj. in stilou injector (pen) preumplut - 20mg - imunosupresoare alte imunosupresoare
metoject pen 22,5 mg
medac gesellscaft fur klinische spezialprÄparate - germania - methotrexatum - sol. inj. in stilou injector (pen) preumplut - 22,5mg - imunosupresoare alte imunosupresoare
metoject pen 25 mg
medac gesellscaft fur klinische spezialprÄparate - germania - methotrexatum - sol. inj. in stilou injector (pen) preumplut - 25mg - imunosupresoare alte imunosupresoare
metoject pen 27,5 mg
medac gesellscaft fur klinische spezialprÄparate - germania - methotrexatum - sol. inj. in stilou injector (pen) preumplut - 27,5mg - imunosupresoare alte imunosupresoare
dacarbazina lipomed 1000 mg
lipomed gmbh - germania - dacarbazinum - pulb. pt. sol. perf. - 1000mg - agenti alchilanti alti agenti alchilanti
dacarbazina lipomed 500 mg
lipomed gmbh - germania - dacarbazinum - pulb. pt. sol. perf. - 500mg - agenti alchilanti alti agenti alchilanti
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.